Welcome to this week’s edition of the Weekender.
New Jersey’s life sciences community continues to provide inspiration, innovation and hope for Patients around the world…
We start this week’s Weekender off with a special call out to precious 6-year old Patient Advocate Max Schill, who won the Abbey Award for Federal Level Advocacy at the 2015 Rare Voice Awards Gala. We are so proud of our Magic Max who was diagnosed at the age of one and a half with Rasopathy, called Noonan Syndrome. A true inspiration, Max has spent a great deal of time and effort traveling to Washington to lobby for the passage of the 21st Century Cures legislation.
The FDA has approved two of BioNJ Member Novartis’ inhalation powders for the treatment of chronic obstructive pulmonary disease.
BioNJ Member Merck has been granted a breakthrough therapy designation from the FDA for pembrolizumab (Keytruda) as a potential therapy for patients with microsatellite instability-high metastatic colorectal cancer.
GlaxoSmithKline won FDA approval for an antibody designed to treat severe asthma, leading a pack of drug makers at work on similar therapies as it seeks to bolster its respiratory business.
BioNJ welcomes the Diaceutics Group to New Jersey and as a new Member of BioNJ and the New Jersey life sciences community. The Diaceutics Group is a dedicated integrator in the personalized or precision medicine space.
Also new to New Jersey is Platinum Press, a Texas manufacturer of drug packaging that has opened a new, state-of-the-art factory in Bergen County.
Join us at BioNJ’s first-ever Inspiring Women in STEM Conference, taking place December 4. Designed to encourage and support women involved in all aspects of STEM, the full-day program features forward-thinking presentations, informative panel discussions, audience participation and valuable networking activities. Register now.
Click here to read this week’s Weekender.